FDA Posting Quarterly Reports of Potential Drug Safety Issues-September 2008

Lauren Green, Associate Editor
Published Online: Thursday, September 18, 2008
Follow Pharmacy_Times:

The first quarterly report by the FDA of drugs that are being evaluated for potential safety issues has been posted to the FDA’s Web site. The list of drugs—identified based on a review of reports in the FDA’s Adverse Event Reporting System (AERS)—is required by Congress as part of FDA amendments signed into law last year.

The agency stresses that the appearance of a drug on this list does not mean that the FDA has concluded the drug has the listed risk, or that the FDA has identified a causal relationship between the drug and the listed risk.

“My message to patients is this: Don’t stop taking your medicine. If your doctor has prescribed a drug that appears on this list, you should continue taking it, unless your doctor advises you differently,” said Janet Woodcock, MD, director of the FDA’s Center for Drug Evaluation and Research.

If a drug appears on the AERS-based quarterly report, it means that the FDA has begun an analysis to determine whether there is a safety problem. Depending on the level of analysis completed, it may be too early to know whether there is a safety problem, and the FDA’s analysis may ultimately conclude there is no safety problem, the FDA notes.

The quarterly reports will not be cumulative; they will list only drugs for which new safety information or potential signals of serious risk have been identified through AERS during the previous 3 months.

More information on the report, “Potential Signals of Serious Risks Identified by AERS,” as well as a listing of the 20 drugs identified for the period January-March 2008, can be found at www.fda.gov/cder/aers.



Related Articles
Joseph Saseen talks about a few things pharmacists should consider with patients who have uncontrolled hypertension and who are taking multiple medications.
Joseph Saseen, PharmD, FASHP, FCCP, FNLA, BCPS, CLS, professor in the Departments of Clinical Pharmacy and Family Medicine at University of Colorado Skaggs School of Pharmacy, talks about the new knowledge surrounding hypertension that we have learned in the past 5 to 10 years.
Joseph Saseen, PharmD, FASHP, FCCP, FNLA, BCPS, CLS, professor in the Departments of Clinical Pharmacy and Family Medicine at University of Colorado Skaggs School of Pharmacy, talks about the role age plays in deciding blood pressure goals.
Joseph Saseen, PharmD, FASHP, FCCP, FNLA, BCPS, CLS, professor in the Departments of Clinical Pharmacy and Family Medicine at University of Colorado Skaggs School of Pharmacy, highlights some of the differences between JNC 8 and the American Society of Hypertension guidelines.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$